Michele Fox
Concepts (432)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 31 | 2017 | 533 | 2.370 |
Why?
| Hematopoietic Stem Cells | 21 | 2018 | 231 | 2.140 |
Why?
| Bone Marrow Transplantation | 28 | 2016 | 164 | 2.120 |
Why?
| Multiple Myeloma | 44 | 2018 | 2750 | 2.070 |
Why?
| Hematopoietic Stem Cell Mobilization | 14 | 2018 | 64 | 1.820 |
Why?
| Antigens, CD34 | 21 | 2018 | 83 | 1.160 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2016 | 1025 | 0.930 |
Why?
| Cell Separation | 8 | 2013 | 115 | 0.920 |
Why?
| Blood Platelets | 5 | 2017 | 306 | 0.890 |
Why?
| Purpura, Thrombotic Thrombocytopenic | 3 | 2018 | 19 | 0.820 |
Why?
| Transplantation, Autologous | 22 | 2013 | 463 | 0.710 |
Why?
| Melphalan | 7 | 2016 | 178 | 0.690 |
Why?
| Graft vs Host Disease | 16 | 2003 | 84 | 0.690 |
Why?
| Leukapheresis | 5 | 2018 | 15 | 0.680 |
Why?
| Blood Component Removal | 5 | 2018 | 19 | 0.630 |
Why?
| Myelodysplastic Syndromes | 3 | 2013 | 82 | 0.630 |
Why?
| Leukocytes, Mononuclear | 5 | 2018 | 140 | 0.560 |
Why?
| Fetal Blood | 3 | 2019 | 58 | 0.550 |
Why?
| Plasma Exchange | 3 | 2015 | 34 | 0.550 |
Why?
| Adult | 49 | 2019 | 14316 | 0.520 |
Why?
| Middle Aged | 44 | 2018 | 13614 | 0.500 |
Why?
| Humans | 88 | 2019 | 52865 | 0.500 |
Why?
| Aged | 33 | 2017 | 10428 | 0.460 |
Why?
| Transplantation Conditioning | 9 | 2006 | 86 | 0.460 |
Why?
| Flow Cytometry | 6 | 2016 | 582 | 0.460 |
Why?
| Killer Cells, Natural | 3 | 2015 | 109 | 0.450 |
Why?
| Granulocyte Colony-Stimulating Factor | 7 | 2012 | 66 | 0.450 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 84 | 0.420 |
Why?
| Transplantation, Homologous | 14 | 2016 | 162 | 0.420 |
Why?
| Chromosome Aberrations | 5 | 2016 | 310 | 0.410 |
Why?
| Female | 50 | 2019 | 28888 | 0.390 |
Why?
| Male | 48 | 2019 | 28240 | 0.390 |
Why?
| Platelet Count | 4 | 2017 | 66 | 0.390 |
Why?
| Cell Proliferation | 5 | 2018 | 1124 | 0.390 |
Why?
| Blood Transfusion | 3 | 2017 | 130 | 0.380 |
Why?
| Antigens, CD | 10 | 2003 | 263 | 0.370 |
Why?
| Thalidomide | 5 | 2016 | 401 | 0.370 |
Why?
| Blood Specimen Collection | 1 | 2019 | 39 | 0.360 |
Why?
| Blood Volume | 1 | 2019 | 74 | 0.360 |
Why?
| Antibodies | 2 | 2016 | 175 | 0.350 |
Why?
| Education, Distance | 1 | 2019 | 41 | 0.350 |
Why?
| Cryopreservation | 3 | 2010 | 36 | 0.340 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 31 | 0.340 |
Why?
| Lymphoma | 3 | 2018 | 62 | 0.340 |
Why?
| Erythrocyte Transfusion | 3 | 2015 | 88 | 0.330 |
Why?
| Graft Survival | 8 | 2011 | 169 | 0.330 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2017 | 45 | 0.330 |
Why?
| Obstetrics | 1 | 2019 | 92 | 0.330 |
Why?
| Blood Grouping and Crossmatching | 1 | 2017 | 6 | 0.320 |
Why?
| Leukemia | 3 | 2013 | 77 | 0.320 |
Why?
| Blood Coagulation | 1 | 2017 | 79 | 0.320 |
Why?
| Leukocytes | 3 | 2011 | 95 | 0.310 |
Why?
| Bone Marrow Cells | 5 | 2004 | 245 | 0.300 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2000 | 48 | 0.290 |
Why?
| Aspirin | 1 | 2017 | 133 | 0.290 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 151 | 0.290 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 209 | 0.280 |
Why?
| Hemoglobins, Abnormal | 1 | 2015 | 4 | 0.280 |
Why?
| Heparin | 1 | 2015 | 101 | 0.270 |
Why?
| Thrombocytopenia | 1 | 2015 | 94 | 0.270 |
Why?
| Combined Modality Therapy | 12 | 2014 | 713 | 0.270 |
Why?
| Stem Cell Transplantation | 2 | 2013 | 193 | 0.270 |
Why?
| Factor VIII | 1 | 2014 | 23 | 0.270 |
Why?
| Methotrexate | 2 | 2001 | 75 | 0.260 |
Why?
| ADAM Proteins | 1 | 2014 | 26 | 0.260 |
Why?
| Anemia, Sickle Cell | 1 | 2015 | 99 | 0.250 |
Why?
| Retroviridae | 4 | 1997 | 12 | 0.240 |
Why?
| Retrospective Studies | 11 | 2018 | 6065 | 0.240 |
Why?
| Neoplasm Recurrence, Local | 3 | 2015 | 596 | 0.240 |
Why?
| Dendritic Cells | 3 | 2010 | 151 | 0.240 |
Why?
| Cancer Vaccines | 3 | 2010 | 106 | 0.240 |
Why?
| Internship and Residency | 1 | 2019 | 493 | 0.240 |
Why?
| Cell Count | 7 | 2011 | 195 | 0.240 |
Why?
| Prognosis | 8 | 2018 | 2104 | 0.240 |
Why?
| Cytomegalovirus Infections | 3 | 2001 | 45 | 0.240 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 41 | 0.240 |
Why?
| Afibrinogenemia | 1 | 2012 | 5 | 0.230 |
Why?
| Graft vs Tumor Effect | 2 | 2006 | 3 | 0.230 |
Why?
| Cell Survival | 7 | 2011 | 693 | 0.220 |
Why?
| Bone Marrow | 8 | 1997 | 413 | 0.220 |
Why?
| Leukemia, Myeloid | 2 | 2000 | 59 | 0.220 |
Why?
| Adenoviridae Infections | 1 | 2001 | 5 | 0.220 |
Why?
| Aldehyde Dehydrogenase | 1 | 2011 | 28 | 0.220 |
Why?
| Gene Transfer Techniques | 3 | 1997 | 43 | 0.220 |
Why?
| Lung Diseases, Fungal | 1 | 2001 | 33 | 0.220 |
Why?
| Tamoxifen | 1 | 2001 | 69 | 0.210 |
Why?
| Treatment Outcome | 19 | 2013 | 5631 | 0.210 |
Why?
| Follow-Up Studies | 10 | 2013 | 2447 | 0.210 |
Why?
| Cyclophosphamide | 8 | 2006 | 190 | 0.210 |
Why?
| Plateletpheresis | 1 | 2010 | 8 | 0.210 |
Why?
| Pyrazines | 2 | 2013 | 204 | 0.210 |
Why?
| Boronic Acids | 2 | 2013 | 200 | 0.210 |
Why?
| Blood Preservation | 1 | 2010 | 31 | 0.200 |
Why?
| Lymphoma, B-Cell | 1 | 2000 | 66 | 0.200 |
Why?
| Myeloablative Agonists | 3 | 2007 | 35 | 0.200 |
Why?
| Blood Proteins | 1 | 2010 | 104 | 0.200 |
Why?
| Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 58 | 0.190 |
Why?
| Anaphylaxis | 1 | 2010 | 71 | 0.190 |
Why?
| Fever | 1 | 2001 | 122 | 0.190 |
Why?
| Immunosuppressive Agents | 4 | 2014 | 256 | 0.190 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 2007 | 100 | 0.190 |
Why?
| Genetic Vectors | 4 | 1997 | 150 | 0.190 |
Why?
| Blood Cells | 4 | 1994 | 57 | 0.180 |
Why?
| Incidence | 7 | 2017 | 1088 | 0.180 |
Why?
| Receptors, KIR | 1 | 2008 | 16 | 0.180 |
Why?
| Etoposide | 6 | 2006 | 89 | 0.180 |
Why?
| HIV Infections | 1 | 2013 | 389 | 0.170 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 896 | 0.160 |
Why?
| Disease-Free Survival | 6 | 2016 | 518 | 0.160 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1995 | 23 | 0.160 |
Why?
| Immunoglobulins, Intravenous | 3 | 1992 | 58 | 0.160 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2001 | 111 | 0.160 |
Why?
| Cell Movement | 2 | 2006 | 301 | 0.160 |
Why?
| Lymphocyte Transfusion | 3 | 2003 | 13 | 0.160 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2001 | 188 | 0.150 |
Why?
| Models, Genetic | 1 | 2006 | 204 | 0.150 |
Why?
| Transformation, Genetic | 1 | 1995 | 19 | 0.150 |
Why?
| Breast Neoplasms | 6 | 1995 | 1272 | 0.150 |
Why?
| Risk Factors | 7 | 2015 | 3984 | 0.140 |
Why?
| Osteogenesis | 2 | 2006 | 378 | 0.140 |
Why?
| Models, Statistical | 1 | 2007 | 267 | 0.140 |
Why?
| Young Adult | 4 | 2019 | 4295 | 0.140 |
Why?
| Antineoplastic Agents | 5 | 2012 | 1290 | 0.140 |
Why?
| Metaphase | 3 | 2016 | 57 | 0.140 |
Why?
| Dimethyl Sulfoxide | 2 | 2010 | 14 | 0.140 |
Why?
| Mycobacterium tuberculosis | 1 | 2007 | 236 | 0.140 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 1995 | 81 | 0.140 |
Why?
| Macrophages | 1 | 2018 | 413 | 0.130 |
Why?
| Gene Expression Profiling | 2 | 2007 | 1118 | 0.130 |
Why?
| Recurrence | 4 | 2008 | 694 | 0.130 |
Why?
| Cytokines | 2 | 2006 | 700 | 0.130 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 318 | 0.130 |
Why?
| Immunoglobulin G | 3 | 2003 | 229 | 0.130 |
Why?
| Risk | 2 | 2017 | 361 | 0.130 |
Why?
| Acute Disease | 4 | 2013 | 417 | 0.130 |
Why?
| Time Factors | 2 | 2010 | 3434 | 0.130 |
Why?
| Postoperative Complications | 2 | 2001 | 1083 | 0.130 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 2016 | 30 | 0.120 |
Why?
| Models, Biological | 2 | 2007 | 872 | 0.120 |
Why?
| Sweet Syndrome | 1 | 2003 | 14 | 0.120 |
Why?
| Dexamethasone | 5 | 2007 | 397 | 0.120 |
Why?
| Neoplasms | 4 | 2007 | 1258 | 0.120 |
Why?
| T-Lymphocyte Subsets | 2 | 2001 | 45 | 0.120 |
Why?
| Bone Diseases | 1 | 2004 | 107 | 0.120 |
Why?
| Cyclosporine | 1 | 2003 | 71 | 0.120 |
Why?
| Tacrolimus | 1 | 2003 | 50 | 0.110 |
Why?
| Osteoblasts | 1 | 2006 | 535 | 0.110 |
Why?
| Prospective Studies | 6 | 2016 | 2453 | 0.110 |
Why?
| Blood Group Incompatibility | 1 | 2002 | 4 | 0.110 |
Why?
| ABO Blood-Group System | 1 | 2002 | 14 | 0.110 |
Why?
| Hemorrhage | 2 | 2017 | 197 | 0.110 |
Why?
| Coculture Techniques | 3 | 2018 | 163 | 0.110 |
Why?
| Kaplan-Meier Estimate | 3 | 2007 | 535 | 0.110 |
Why?
| Genetic Therapy | 3 | 1995 | 117 | 0.110 |
Why?
| T-Lymphocytes | 2 | 1998 | 340 | 0.110 |
Why?
| Cryoprotective Agents | 2 | 1998 | 5 | 0.110 |
Why?
| Ovarian Neoplasms | 1 | 1995 | 447 | 0.110 |
Why?
| Lymphoma, Mantle-Cell | 2 | 2001 | 19 | 0.100 |
Why?
| Hodgkin Disease | 2 | 2002 | 49 | 0.100 |
Why?
| Platelet Transfusion | 2 | 2010 | 34 | 0.100 |
Why?
| Lymphocyte Depletion | 3 | 1996 | 13 | 0.100 |
Why?
| Osteoclasts | 1 | 2004 | 461 | 0.100 |
Why?
| Tissue Preservation | 2 | 1998 | 8 | 0.100 |
Why?
| Cyclosporins | 2 | 1991 | 11 | 0.100 |
Why?
| Tissue Donors | 3 | 2003 | 105 | 0.100 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2012 | 77 | 0.100 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 76 | 0.100 |
Why?
| Heart Failure | 1 | 2006 | 548 | 0.100 |
Why?
| Lung Diseases | 1 | 2001 | 99 | 0.100 |
Why?
| Vaccines, DNA | 1 | 1999 | 23 | 0.100 |
Why?
| Thrombosis | 1 | 2003 | 263 | 0.090 |
Why?
| Erythroid Precursor Cells | 1 | 2019 | 19 | 0.090 |
Why?
| Blood Banks | 1 | 2019 | 18 | 0.090 |
Why?
| Adolescent | 6 | 2015 | 6866 | 0.090 |
Why?
| Birth Weight | 1 | 2019 | 113 | 0.090 |
Why?
| Logistic Models | 3 | 2017 | 1028 | 0.090 |
Why?
| Reproducibility of Results | 3 | 2017 | 1326 | 0.090 |
Why?
| Graft vs Host Reaction | 1 | 1998 | 2 | 0.090 |
Why?
| Salvage Therapy | 3 | 2003 | 146 | 0.090 |
Why?
| Hematocrit | 1 | 2018 | 53 | 0.090 |
Why?
| Cisplatin | 4 | 2006 | 348 | 0.090 |
Why?
| Antigens, Neoplasm | 2 | 2005 | 170 | 0.080 |
Why?
| Cell Aggregation | 1 | 2017 | 8 | 0.080 |
Why?
| Medical Waste | 1 | 2017 | 4 | 0.080 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2008 | 77 | 0.080 |
Why?
| Survival Analysis | 6 | 2006 | 791 | 0.080 |
Why?
| Neutrophils | 2 | 2006 | 162 | 0.080 |
Why?
| Lymphoma, Follicular | 1 | 2017 | 26 | 0.080 |
Why?
| Histocompatibility Antigens Class I | 1 | 2017 | 47 | 0.080 |
Why?
| Lung | 1 | 2001 | 489 | 0.080 |
Why?
| Program Evaluation | 1 | 2019 | 403 | 0.080 |
Why?
| Arkansas | 2 | 2017 | 2175 | 0.080 |
Why?
| Lymphocyte Activation | 2 | 1995 | 212 | 0.080 |
Why?
| Infant, Newborn | 2 | 2019 | 2767 | 0.080 |
Why?
| Neoplasm Proteins | 2 | 2016 | 387 | 0.080 |
Why?
| Fibrosis | 1 | 2017 | 216 | 0.080 |
Why?
| Reticulocyte Count | 1 | 2006 | 7 | 0.070 |
Why?
| Tumor Escape | 1 | 2006 | 23 | 0.070 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 102 | 0.070 |
Why?
| Antibodies, Monoclonal | 2 | 2002 | 562 | 0.070 |
Why?
| Glucosylceramidase | 1 | 1995 | 11 | 0.070 |
Why?
| Curriculum | 1 | 2019 | 417 | 0.070 |
Why?
| Prostatic Neoplasms | 1 | 1999 | 413 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 3 | 2008 | 1571 | 0.070 |
Why?
| Cytogenetic Analysis | 2 | 2007 | 79 | 0.070 |
Why?
| Neutropenia | 1 | 2006 | 117 | 0.070 |
Why?
| Hematologic Neoplasms | 1 | 1996 | 89 | 0.070 |
Why?
| Hemoglobin J | 1 | 2015 | 3 | 0.070 |
Why?
| Hemoglobin, Sickle | 1 | 2015 | 7 | 0.070 |
Why?
| Hemoglobin C | 1 | 2015 | 7 | 0.070 |
Why?
| Membrane Glycoproteins | 3 | 2004 | 295 | 0.070 |
Why?
| Mice | 5 | 2018 | 6389 | 0.070 |
Why?
| Blood Donors | 1 | 2015 | 40 | 0.070 |
Why?
| Clinical Protocols | 2 | 2012 | 128 | 0.070 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2007 | 445 | 0.060 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1184 | 0.060 |
Why?
| Autoantibodies | 1 | 2014 | 123 | 0.060 |
Why?
| Aged, 80 and over | 3 | 2013 | 3624 | 0.060 |
Why?
| Specimen Handling | 1 | 1994 | 63 | 0.060 |
Why?
| Feasibility Studies | 2 | 2011 | 403 | 0.060 |
Why?
| Cell Line | 2 | 2008 | 1226 | 0.060 |
Why?
| Base Sequence | 3 | 1995 | 773 | 0.060 |
Why?
| Prednisone | 2 | 2000 | 116 | 0.060 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 36 | 0.060 |
Why?
| Interferon-gamma | 2 | 2010 | 201 | 0.060 |
Why?
| Age Factors | 3 | 2005 | 1262 | 0.060 |
Why?
| Whole-Body Irradiation | 4 | 1998 | 163 | 0.060 |
Why?
| Blotting, Western | 1 | 2015 | 721 | 0.060 |
Why?
| Multivariate Analysis | 3 | 2007 | 698 | 0.060 |
Why?
| Pulmonary Fibrosis | 2 | 1991 | 22 | 0.060 |
Why?
| Molecular Sequence Data | 3 | 1995 | 1053 | 0.060 |
Why?
| Viral Load | 1 | 2013 | 87 | 0.060 |
Why?
| Quality Assurance, Health Care | 1 | 1994 | 169 | 0.060 |
Why?
| Transplantation Chimera | 3 | 2003 | 17 | 0.060 |
Why?
| Pharmacokinetics | 1 | 1992 | 17 | 0.060 |
Why?
| Immunization, Passive | 1 | 1992 | 36 | 0.060 |
Why?
| Bone Marrow Purging | 1 | 1992 | 2 | 0.060 |
Why?
| Benzylamines | 1 | 2012 | 19 | 0.060 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 33 | 0.060 |
Why?
| Haplotypes | 2 | 2008 | 110 | 0.060 |
Why?
| Heterocyclic Compounds | 1 | 2012 | 31 | 0.060 |
Why?
| Animals | 6 | 2018 | 14801 | 0.060 |
Why?
| Immunoglobulins | 1 | 1992 | 87 | 0.060 |
Why?
| Infection Control | 1 | 1992 | 58 | 0.060 |
Why?
| Kanamycin Kinase | 2 | 1995 | 2 | 0.050 |
Why?
| Carmustine | 1 | 2001 | 13 | 0.050 |
Why?
| Cohort Studies | 3 | 2006 | 1532 | 0.050 |
Why?
| Pneumonia, Pneumocystis | 1 | 2001 | 7 | 0.050 |
Why?
| Urine | 1 | 1991 | 37 | 0.050 |
Why?
| Pregnancy | 1 | 2019 | 2432 | 0.050 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2002 | 61 | 0.050 |
Why?
| Microscopy, Electron | 1 | 2001 | 98 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2008 | 594 | 0.050 |
Why?
| Immunohistochemistry | 1 | 2015 | 1140 | 0.050 |
Why?
| Child | 5 | 2015 | 6934 | 0.050 |
Why?
| Foscarnet | 1 | 2001 | 4 | 0.050 |
Why?
| Immune Tolerance | 1 | 2011 | 104 | 0.050 |
Why?
| DNA Primers | 2 | 1995 | 242 | 0.050 |
Why?
| Ganciclovir | 1 | 2001 | 37 | 0.050 |
Why?
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 8 | 0.050 |
Why?
| Cytomegalovirus | 1 | 2001 | 29 | 0.050 |
Why?
| Quality Control | 3 | 2005 | 98 | 0.050 |
Why?
| Chimera | 1 | 1990 | 14 | 0.050 |
Why?
| Tumor Cells, Cultured | 2 | 1996 | 528 | 0.050 |
Why?
| Isotonic Solutions | 1 | 2010 | 22 | 0.050 |
Why?
| Virus Activation | 1 | 2001 | 29 | 0.050 |
Why?
| P-Selectin | 1 | 2010 | 43 | 0.050 |
Why?
| Anemia, Aplastic | 1 | 1990 | 12 | 0.050 |
Why?
| Antigens, Viral | 1 | 2001 | 57 | 0.050 |
Why?
| Fatal Outcome | 1 | 2001 | 234 | 0.050 |
Why?
| Syndrome | 1 | 2001 | 259 | 0.050 |
Why?
| Sodium Chloride | 1 | 2010 | 68 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2001 | 175 | 0.050 |
Why?
| Platelet Aggregation | 1 | 2010 | 93 | 0.050 |
Why?
| Transfection | 3 | 1999 | 439 | 0.050 |
Why?
| Platelet Activation | 1 | 2010 | 67 | 0.050 |
Why?
| Angiogenesis Inhibitors | 2 | 2007 | 215 | 0.050 |
Why?
| Hypersensitivity | 1 | 2010 | 74 | 0.050 |
Why?
| Algorithms | 2 | 2005 | 729 | 0.050 |
Why?
| Polyomavirus | 1 | 1989 | 5 | 0.050 |
Why?
| Peripheral Nervous System Diseases | 1 | 1990 | 61 | 0.050 |
Why?
| Leukemia, Myeloid, Acute | 2 | 2007 | 172 | 0.050 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1067 | 0.050 |
Why?
| Cystitis | 1 | 1989 | 21 | 0.050 |
Why?
| Antiviral Agents | 1 | 2001 | 185 | 0.050 |
Why?
| Ultraviolet Rays | 1 | 1989 | 56 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 1995 | 556 | 0.040 |
Why?
| Clone Cells | 2 | 2006 | 86 | 0.040 |
Why?
| Arginase | 1 | 2018 | 33 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2018 | 84 | 0.040 |
Why?
| Glucocorticoids | 1 | 2000 | 285 | 0.040 |
Why?
| Ligands | 1 | 2008 | 254 | 0.040 |
Why?
| Hemoglobins | 1 | 2008 | 124 | 0.040 |
Why?
| Polyethylene Glycols | 1 | 2008 | 98 | 0.040 |
Why?
| Pilot Projects | 1 | 2000 | 805 | 0.040 |
Why?
| Carrier Proteins | 2 | 2004 | 377 | 0.040 |
Why?
| DNA | 1 | 1991 | 586 | 0.040 |
Why?
| Age Distribution | 1 | 2007 | 210 | 0.040 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 54 | 0.040 |
Why?
| Theophylline | 1 | 2007 | 22 | 0.040 |
Why?
| Multigene Family | 1 | 2006 | 67 | 0.040 |
Why?
| Chromosome Deletion | 1 | 2007 | 150 | 0.040 |
Why?
| Chromosome Mapping | 1 | 2006 | 175 | 0.040 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2007 | 273 | 0.040 |
Why?
| 3T3 Cells | 1 | 1995 | 58 | 0.040 |
Why?
| Cytotoxicity, Immunologic | 1 | 1995 | 63 | 0.040 |
Why?
| Interleukin-2 | 1 | 1995 | 82 | 0.040 |
Why?
| Cell Communication | 1 | 2006 | 73 | 0.040 |
Why?
| Interleukin-10 | 1 | 2006 | 108 | 0.040 |
Why?
| Neoplasms, Experimental | 1 | 2006 | 119 | 0.030 |
Why?
| Life Tables | 2 | 2002 | 9 | 0.030 |
Why?
| Stroke Volume | 1 | 2006 | 139 | 0.030 |
Why?
| Apoptosis | 1 | 2001 | 1357 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2006 | 103 | 0.030 |
Why?
| Ficoll | 2 | 1996 | 4 | 0.030 |
Why?
| Liver | 1 | 2001 | 1266 | 0.030 |
Why?
| Annexin A5 | 1 | 2004 | 15 | 0.030 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2004 | 38 | 0.030 |
Why?
| Bromodeoxyuridine | 1 | 2004 | 22 | 0.030 |
Why?
| Databases, Factual | 1 | 2007 | 698 | 0.030 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 52 | 0.030 |
Why?
| Phagocytosis | 1 | 2004 | 48 | 0.030 |
Why?
| Myocardial Ischemia | 1 | 2006 | 150 | 0.030 |
Why?
| Immunotherapy | 2 | 2002 | 248 | 0.030 |
Why?
| Survival Rate | 1 | 2006 | 1012 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2006 | 725 | 0.030 |
Why?
| Syndecans | 1 | 2003 | 46 | 0.030 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 30 | 0.030 |
Why?
| Paraproteins | 1 | 2003 | 13 | 0.030 |
Why?
| Ifosfamide | 2 | 1993 | 7 | 0.030 |
Why?
| Syndecan-1 | 1 | 2003 | 82 | 0.030 |
Why?
| Plasmapheresis | 1 | 2003 | 14 | 0.030 |
Why?
| Cell Division | 1 | 2004 | 369 | 0.030 |
Why?
| Proteoglycans | 1 | 2003 | 97 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 173 | 0.030 |
Why?
| Chronic Disease | 1 | 2006 | 625 | 0.030 |
Why?
| RANK Ligand | 1 | 2004 | 189 | 0.030 |
Why?
| Remission Induction | 2 | 2003 | 223 | 0.030 |
Why?
| Interleukin-6 | 1 | 2004 | 318 | 0.030 |
Why?
| Red-Cell Aplasia, Pure | 1 | 2002 | 9 | 0.030 |
Why?
| Infusions, Intravenous | 2 | 2003 | 245 | 0.030 |
Why?
| Blood Transfusion, Autologous | 2 | 1992 | 7 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2003 | 425 | 0.030 |
Why?
| NF-kappa B | 1 | 2004 | 350 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2006 | 1113 | 0.030 |
Why?
| Gene Rearrangement, T-Lymphocyte | 1 | 2001 | 2 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2001 | 26 | 0.030 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2001 | 44 | 0.030 |
Why?
| Graft Rejection | 1 | 2002 | 163 | 0.030 |
Why?
| Colony-Forming Units Assay | 2 | 1992 | 34 | 0.030 |
Why?
| CD40 Ligand | 1 | 2010 | 18 | 0.030 |
Why?
| Drug Resistance, Neoplasm | 2 | 2003 | 297 | 0.030 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 18 | 0.030 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.030 |
Why?
| Cell Differentiation | 1 | 2004 | 757 | 0.030 |
Why?
| Interleukin-4 | 1 | 2010 | 51 | 0.030 |
Why?
| Immunity, Cellular | 1 | 2010 | 85 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 64 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2006 | 1693 | 0.020 |
Why?
| Biotechnology | 1 | 1999 | 16 | 0.020 |
Why?
| Immunologic Surveillance | 1 | 1999 | 18 | 0.020 |
Why?
| B-Lymphocytes | 1 | 2010 | 187 | 0.020 |
Why?
| Child, Preschool | 3 | 1994 | 4140 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2007 | 1710 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 712 | 0.020 |
Why?
| Transcription, Genetic | 1 | 2001 | 465 | 0.020 |
Why?
| Vaccination | 1 | 2010 | 213 | 0.020 |
Why?
| Drug Resistance | 1 | 1998 | 80 | 0.020 |
Why?
| Steroids | 1 | 1998 | 56 | 0.020 |
Why?
| Chromatography, Gas | 1 | 1998 | 21 | 0.020 |
Why?
| Neomycin | 1 | 1997 | 4 | 0.020 |
Why?
| Secondary Prevention | 1 | 1998 | 88 | 0.020 |
Why?
| Drug Resistance, Microbial | 1 | 1997 | 45 | 0.020 |
Why?
| Leukemia, Erythroblastic, Acute | 1 | 1996 | 6 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 1996 | 25 | 0.020 |
Why?
| Solutions | 1 | 1996 | 30 | 0.020 |
Why?
| Indicators and Reagents | 1 | 1996 | 58 | 0.020 |
Why?
| Stromal Cells | 1 | 1997 | 98 | 0.020 |
Why?
| Deoxycytidine | 1 | 2006 | 30 | 0.020 |
Why?
| Temperature | 1 | 1996 | 176 | 0.020 |
Why?
| Genes | 1 | 1995 | 40 | 0.020 |
Why?
| Transduction, Genetic | 1 | 1995 | 52 | 0.020 |
Why?
| In Situ Hybridization | 1 | 1995 | 88 | 0.020 |
Why?
| Chromatography, Affinity | 1 | 1995 | 48 | 0.020 |
Why?
| Genes, Reporter | 1 | 1995 | 116 | 0.020 |
Why?
| Fluorouracil | 1 | 1995 | 74 | 0.020 |
Why?
| Genetic Markers | 1 | 1995 | 124 | 0.020 |
Why?
| Lymphocyte Subsets | 1 | 1994 | 19 | 0.020 |
Why?
| Recovery of Function | 1 | 2006 | 236 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 1995 | 380 | 0.020 |
Why?
| Propidium | 1 | 1994 | 3 | 0.020 |
Why?
| Macaca mulatta | 1 | 1994 | 113 | 0.020 |
Why?
| Kinetics | 1 | 2006 | 740 | 0.020 |
Why?
| Immunophenotyping | 1 | 1994 | 128 | 0.020 |
Why?
| Oligodeoxyribonucleotides | 1 | 1993 | 33 | 0.020 |
Why?
| Stem Cell Factor | 1 | 2003 | 8 | 0.020 |
Why?
| Confidence Intervals | 1 | 2003 | 177 | 0.020 |
Why?
| Probability | 1 | 2003 | 186 | 0.020 |
Why?
| Cell Nucleus | 1 | 1994 | 220 | 0.010 |
Why?
| Leukocyte Count | 1 | 2003 | 81 | 0.010 |
Why?
| Data Interpretation, Statistical | 1 | 1994 | 185 | 0.010 |
Why?
| Cell Death | 1 | 1994 | 238 | 0.010 |
Why?
| Carboplatin | 1 | 1992 | 54 | 0.010 |
Why?
| Academic Medical Centers | 1 | 1994 | 155 | 0.010 |
Why?
| Mutation | 1 | 1999 | 1428 | 0.010 |
Why?
| Multiple Organ Failure | 1 | 2002 | 56 | 0.010 |
Why?
| Leukopenia | 1 | 1992 | 10 | 0.010 |
Why?
| Neoplasm Metastasis | 1 | 1993 | 263 | 0.010 |
Why?
| Injections, Intravenous | 1 | 1992 | 161 | 0.010 |
Why?
| Statistics as Topic | 1 | 1992 | 108 | 0.010 |
Why?
| Blood Cell Count | 1 | 1992 | 43 | 0.010 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 54 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 481 | 0.010 |
Why?
| Rats | 1 | 1998 | 3599 | 0.010 |
Why?
| Doxorubicin | 1 | 2003 | 266 | 0.010 |
Why?
| Linear Models | 1 | 1992 | 322 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 1992 | 458 | 0.010 |
Why?
| HLA Antigens | 1 | 1990 | 53 | 0.010 |
Why?
| Pedigree | 1 | 1990 | 140 | 0.010 |
Why?
| Muscle Cramp | 1 | 1990 | 5 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2003 | 809 | 0.010 |
Why?
| Bacterial Infections | 1 | 1991 | 105 | 0.010 |
Why?
| Mycoses | 1 | 1991 | 154 | 0.010 |
Why?
| Postoperative Period | 1 | 1990 | 200 | 0.010 |
Why?
| Software | 1 | 1992 | 281 | 0.010 |
Why?
| Busulfan | 1 | 1989 | 18 | 0.010 |
Why?
| Disease Progression | 1 | 2003 | 898 | 0.010 |
Why?
| Sepsis | 1 | 2002 | 239 | 0.010 |
Why?
| Tumor Virus Infections | 1 | 1989 | 44 | 0.010 |
Why?
| Hematopoiesis | 1 | 1989 | 85 | 0.010 |
Why?
| Dose-Response Relationship, Radiation | 1 | 1989 | 213 | 0.010 |
Why?
| Infant | 1 | 1990 | 3694 | 0.010 |
Why?
|
|
Fox's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|